Efficacy of Favipiravir in treatment of mild & moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial

PURPOSE: To study tolerability and outcome of oral favipiravir treatment among COVID-19 patients in Nepal. METHODS & MATERIALS: In this multi-centered randomized, open-labelled phase III clinical trial, we enrolled 18-80 years old, RT-PCR confirmed patients with mild to moderate COVID-19 infecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhikari, P., Koirala, J., Shrestha, A., Bista, N., Maleku, K., Das, J., Bhandari, K., Adhikari, N., Rawal, A., Pandit, K., Gyawali, P., Pant, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Ps05.17 (818)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884842/
http://dx.doi.org/10.1016/j.ijid.2021.12.109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884842/
http://dx.doi.org/10.1016/j.ijid.2021.12.109

Ejemplares similares